Myo-Inositol for Reproductive Health

Myo-inositol has become a mainstream first-line option in PCOS-related subfertility, and the evidence base is genuinely fertility-specific rather than extrapolated. A 2018 BJOG meta-analysis of randomised trials found inositol treatment improved ovulation in women with polycystic ovary syndrome. A 2018 Cochrane review of inositol for subfertile women with polycystic ovary syndrome examined the same question with more conservative methodology.

The Cochrane conclusion is the important nuance: ovulation and hormonal markers improve reasonably consistently, but evidence for live birth, the outcome that actually matters, remains uncertain because trials were small and short. So the fair statement is that myo-inositol reliably improves the mechanism of fertility in PCOS, and probably improves conception, while proof of higher live birth rates is still thin. It is not a general fertility supplement: outside PCOS and insulin resistance, there is little reason to expect benefit.

Myo-inositol is a sugar alcohol that functions as a second messenger in insulin signalling. Inside the cell it is converted to inositol phosphoglycans, which mediate part of the insulin response, and in PCOS this conversion is impaired. The result is cellular insulin resistance despite adequate circulating inositol, which is why supplementation can improve insulin sensitivity where the defect is post-receptor.

That matters for fertility because hyperinsulinaemia drives ovarian androgen production and disrupts follicular development. Lowering insulin lowers ovarian testosterone, restores more normal LH to FSH signalling and allows follicles to mature and ovulate rather than arresting. Myo-inositol is also directly concentrated in follicular fluid, where it is involved in oocyte maturation and meiotic competence, and higher follicular fluid concentrations correlate with better oocyte quality. The 40 to 1 ratio of myo-inositol to D-chiro-inositol used in most products reflects the physiological ratio in plasma, which appears to matter because excess D-chiro-inositol may impair oocyte quality.

The standard trial regimen is 2 g of myo-inositol twice daily, giving 4 g per day, usually combined with 400 micrograms of folic acid. Most products use a 40 to 1 myo-inositol to D-chiro-inositol ratio. Allow three to six months, since ovulatory cycles take time to re-establish and improvements in insulin markers appear over roughly 8 to 12 weeks. Powder dissolved in water is easier than swallowing multiple large capsules. Taking it with meals reduces the mild bloating some people notice initially.

Two linked reviews support this pairing: a 2018 Cochrane Database of Systematic Reviews assessment of inositol for subfertile women with polycystic ovary syndrome, and a 2018 BJOG meta-analysis of randomised trials of inositol treatment for anovulation in PCOS. The BJOG meta-analysis found improved ovulation. Cochrane graded the evidence for live birth as uncertain, reflecting small trial sizes, short follow-up, varied inositol formulations and inconsistent reporting of clinical pregnancy. Both agree the safety profile is favourable and that larger trials with birth outcomes are needed.

Myo-inositol is well tolerated at 4 g per day. The commonest side effects are mild nausea, bloating and loose stools, generally at higher doses and often settling within a couple of weeks. Unlike metformin, it does not cause the same degree of gastrointestinal intolerance, which is one reason for its popularity. It is naturally present in food and produced endogenously. Doses above about 12 g per day are more likely to cause gastrointestinal upset. It is widely used in preconception and has a reassuring profile, but discuss it with your fertility team if you are undergoing assisted reproduction.

Myo-inositol lowers insulin, so combining it with metformin or insulin-sensitising treatment can be additive; this is often intentional but worth monitoring. It may also enhance ovulation induction agents such as clomiphene or letrozole, which is generally desirable but should be supervised. High-dose D-chiro-inositol alone is the main product-level conflict, since excess appears to impair oocyte quality. Untreated thyroid disease and elevated prolactin also block conception and need correcting independently.